Efrat Finkin-Groner, PhD, serves as a Lead of Drug Development in the MSK Therapeutics Bridge Labs (TxBL) program, based the Office of Entrepreneurship & Commercialization. Her responsibilities include leading biologics and small molecule programs from target validation through completion, as well as providing expertise in assay development and implementation. Efrat also manages an internal bioassay protocol library to support best practices in assay development across the scientific community. She joined MSK in September 2025.
Previously, Efrat served as a director of biology at the Sanders Tri-Institutional Therapeutics Discovery Institute. She earlier was a postdoctoral fellow at the Tri-Institutional Therapeutics Discovery Institute, where she was subsequently recruited as a full-time scientist. Prior to that, she completed postdoctoral training at MSK in the lab of Dr. Yael David, where she worked on generating semi-synthetic histones.
Efrat received her bachelor’s degree in chemistry from the Hebrew University of Jerusalem in 2004, followed by an M.Sc. in Pharmacology in 2007 and a PhD in Pharmacology in 2013. In parallel with her doctoral studies, she earned a B.Sc. in Pharmacy in 2012.